Impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective French trial.

Details

Ressource 1Download: 29644007_BIB_289EF15FCDC6.pdf (3123.36 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_289EF15FCDC6
Type
Article: article from journal or magazin.
Collection
Publications
Title
Impact of adjuvant hormonotherapy on radiation-induced breast fibrosis according to the individual radiosensitivity: results of a multicenter prospective French trial.
Journal
Oncotarget
Author(s)
Bourgier C., Castan F., Riou O., Nguyen T.D., Peignaux K., Lemanski C., Lagrange J.L., Kirova Y., Lartigau E., Belkacemi Y., Rivera S., Noël G., Clippe S., Mornex F., Hennequin C., Gourgou S., Brengues M., Fenoglietto P., Ozsahin E.M., Azria D.
ISSN
1949-2553 (Electronic)
ISSN-L
1949-2553
Publication state
Published
Issued date
20/03/2018
Peer-reviewed
Oui
Volume
9
Number
21
Pages
15757-15765
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
To evaluate risk of severe breast fibrosis occurrence in patients treated by breast-conserving surgery, adjuvant radiotherapy and hormonotherapy (HT) according to individual radiosensitivity (RILA assay).
HT <sup>-</sup> and RILA <sup>high</sup> were the two independent factors associated with improved breast-fibrosis free survival (BFFS). BFFS rate at 36 months was lower in patients with RILA <sup>low</sup> and HT <sup>+</sup> than in patients with RILA <sup>high</sup> and HT <sup>-</sup> (75.8% and 100%, respectively; <i>p</i> = 0.004, hazard ratio 5.84 [95% confidence interval (CI) 1.8-19.1]). Conversely, BFFS at 36 months was comparable in patients with RILA <sup>high</sup> and HT <sup>+</sup> and in patients with RILA <sup>low</sup> and HT <sup>-</sup> (89.8% and 93.5%, respectively; <i>p</i> = 0.39, hazard ratio 1.7 [95% CI 0.51-5.65]), showing that these two parameters influenced independently the occurrence of severe breast fibrosis. BFFS rate was not affected by the HT type (tamoxifen or aromatase inhibitor) and timing (concomitant or sequential with radiotherapy).
HT and RILA score independently influenced BFFS rate at 36 months. Patients with RILA <sup>high</sup> and HT <sup>-</sup> presented an excellent BFFS at 36 months (100%).
Breast Fibrosis-Free Survival (BFFS) rate was assessed relative to RILA categories and to adjuvant HT use (HT <sup>+</sup> and HT <sup>-</sup> , respectively) in a prospective multicentre study (NCT00893035) which enrolled 502 breast cancer patients (456 evaluable patients). Breast fibrosis was recorded according to CTCAE v3.0 grading scale; RILA score was defined according to two categories (<12%: RILA <sup>low</sup> ; ≥12%: RILA <sup>high</sup> ).

Keywords
breast cancer, hormonotherapy, individual radiosensitivity, late effects, radiotherapy
Pubmed
Open Access
Yes
Create date
19/04/2018 20:06
Last modification date
20/08/2019 13:08
Usage data